Pfizer’s COVID-19 shot offers long term protection for young teens, according to data from the company.
Pfizer said Monday a late-stage study showed its two-dose vaccine was 100% effective in preventing infections in kids aged 12 to 15 from seven days through four months after the second dose.
The vaccine it developed with BioNTech got the nod from U.S. regulators for emergency use for young teens back in May. The new long-term data will support the company's planned submissions for full regulatory approval for that age group.
U.S. regulators have already granted Pfizer’s shot full approval for use in people aged 16 and older.
Shares of Pfizer rose in early trading Monday. They have now gained 39% this year.